News

The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how FDA hopes to fix it.

A new Swedish study examined gender differences in rheumatism and other autoimmune diseases. Here are the surprising findings.

Executives from diagnostics, payer, pharma, and patient care companies recently got together to share stakeholder insights on outcomes-based contracting.

Here’s what’s shaking up the drug launch pricing space. Experts weigh in.

Managed Healthcare Executive asked experts to identify Trump’s top priorities within the plan, and how those priorities could affect managed care.

Managed Healthcare Executive asked experts to weigh in on Trump’s new blueprint to tackle drug market challenges. Here’s what they said.

According to research-backed statistics, telepsychiatry improves the behavioral health outlook for today’s veterans.

Home-based palliative care helps ACOs manage fast-growing senior population with a serious or advanced illness, provide quality care, and generate cost savings that enable ongoing participation in the Medicare Shared Savings Program.

Managed Healthcare Executive asked healthcare executives about their interview techniques, how they approach job interviews, and the one doozy of a question that they like to ask job candidates. Here’s what they said.

FDA issued a recall of popular blood pressure drugs. Here’s what you need to know.

A new HealthMine survey of Medicare beneficiaries has surprising results about this population’s digital health literacy.

Payers are becoming more receptive to a different approach for paying for addiction treatment and recovery services, as evidenced by the formation of a new healthcare alliance that aims to redesign the structure and payment of these services.

If all consumers had a high understanding of how to navigate the healthcare system, health insurers could save billions of dollars a year. Here’s what you should do.

Making medications more affordable to patients is linked to better adherence, with no added costs, according to a new study.

Here’s how healthcare can do more to help patients learn more about their health to better prepare them to participate in their own treatment.

Glucose monitoring technology could become the go-to management strategy in a few years. Here’s where we are and where we are going.

FDA okayed a first-of-its-kind treatment for hairy cell leukemia (HCL).

Here are 4 key ways healthcare executives can leverage community resources to strengthen the availability of tools that support recovery from opioid addiction.

Payers struggle to determine the appropriate criteria for covering innovative treatments and providers want to increase patient access. Patients’ lives can hang in the balance.

A South Korean study may contribute to the improvement of personalized therapeutic outcomes for rheumatoid arthritis by expanding the scope of molecular imaging.

NORC at the University of Chicago set out to understand more Americans’ experiences with surprise billing. You won’t believe what they found.

A new study on the overlap between the causes of rheumatoid arthritis and Huntington’s disease opens up new therapeutic targets and drugs for both conditions.

Onboarding new oncology patients can be a delicate process to help them prepare for their care journey. Here are the first steps.

Surprising findings from the largest study to date investigating the genetics of osteoporosis and fracture risk.

Plenty of M&A deals look great on paper but ultimately fall apart in the post-deal integration phase. Here are the biggest pitfalls healthcare executives and stakeholders on both sides of a deal need to consider when managing this critical phase of the process.

FDA recently approved 2 new treatments, heightening competition in the HIV-1 drug marketplace.

FDA cleared the first and only easy-to-swallow liquid drug to treat amyotrophic lateral sclerosis (ALS).

While promising new options keep entering the scene, high costs can be problematic to patients and healthcare organizations. Here are some ways to cope.

The latest lymphoma research continues to bring new hope for patents, families and care providers. In looking at such advances, here are four things to know.